Sanuwave Shares Plunge After Revenue Guidance Cut

Dow Jones

Oct 07

By Freddy Sebastian

Sanuwave Health said it expects third-quarter revenue of $11.4 million to $11.6 million, below its previous expectations, blaming uncertainty around proposed reimbursement changes for some treatment modalities.

Its stock dropped 20.4% to $32.50 in after-hours trading on Monday.

The company, which develops patented noninvasive, biological response activating devices, previously expected revenue between $12 million and $12.7 million for its three-month period ended Sept. 30.

The uncertainty affected purchase decisions, which were delayed and patient counts were reduced as providers took a wait-and-see approach to potential changes, CEO Morgan Frank said. "This made for a difficult environment," he added.

As a result, Sanuwave said it cut its revenue forecast for fiscal 2025 to between $44 million to $46 million from previous guidance of $48 million to $50 million.

Write to Freddy Sebastian at freddy.sebastian@wsj.com

(END) Dow Jones Newswires

October 06, 2025 16:52 ET (20:52 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2573985561"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573985561\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573985561?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-07 04:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573985561","market":"us","top_or_hot":-1,"title":"Sanuwave Shares Plunge After Revenue Guidance Cut","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Freddy Sebastian \n</p>\n<p>\n  Sanuwave Health said it expects third-quarter revenue of $11.4 million to $11.6 million, below its previous expectations, blaming uncertainty around proposed reimbursement changes for some treatment modalities. \n</p>\n<p>\n  Its stock dropped 20.4% to $32.50 in after-hours trading on Monday. \n</p>\n<p>\n  The company, which develops patented noninvasive, biological response activating devices, previously expected revenue between $12 million and $12.7 million for its three-month period ended Sept. 30. \n</p>\n<p>\n  The uncertainty affected purchase decisions, which were delayed and patient counts were reduced as providers took a wait-and-see approach to potential changes, CEO Morgan Frank said. \"This made for a difficult environment,\" he added. \n</p>\n<p>\n  As a result, Sanuwave said it cut its revenue forecast for fiscal 2025 to between $44 million to $46 million from previous guidance of $48 million to $50 million. \n</p>\n<p>\n  Write to Freddy Sebastian at freddy.sebastian@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 06, 2025 16:52 ET (20:52 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanuwave Shares Plunge After Revenue Guidance Cut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanuwave Shares Plunge After Revenue Guidance Cut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-07 04:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Freddy Sebastian \n</p>\n<p>\n  Sanuwave Health said it expects third-quarter revenue of $11.4 million to $11.6 million, below its previous expectations, blaming uncertainty around proposed reimbursement changes for some treatment modalities. \n</p>\n<p>\n  Its stock dropped 20.4% to $32.50 in after-hours trading on Monday. \n</p>\n<p>\n  The company, which develops patented noninvasive, biological response activating devices, previously expected revenue between $12 million and $12.7 million for its three-month period ended Sept. 30. \n</p>\n<p>\n  The uncertainty affected purchase decisions, which were delayed and patient counts were reduced as providers took a wait-and-see approach to potential changes, CEO Morgan Frank said. \"This made for a difficult environment,\" he added. \n</p>\n<p>\n  As a result, Sanuwave said it cut its revenue forecast for fiscal 2025 to between $44 million to $46 million from previous guidance of $48 million to $50 million. \n</p>\n<p>\n  Write to Freddy Sebastian at freddy.sebastian@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 06, 2025 16:52 ET (20:52 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNWV","symbol_name":"SANUWAVE Health, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2573985561","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573985561","pubTimestamp":1759783920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Sanuwave Health said it expects third-quarter revenue of $11.4 million to $11.6 million, below its previous expectations, blaming uncertainty around proposed reimbursement changes for some treatment modalities.Its stock dropped 20.4% to $32.50 in after-hours trading on Monday.The company, which develops patented noninvasive, biological response activating devices, previously expected revenue between $12 million and $12.7 million for its three-month period ended Sept. 30.The uncertainty affected purchase decisions, which were delayed and patient counts were reduced as providers took a wait-and-see approach to potential changes, CEO Morgan Frank said. \"This made for a difficult environment,\" he added.As a result, Sanuwave said it cut its revenue forecast for fiscal 2025 to between $44 million to $46 million from previous guidance of $48 million to $50 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNWV":"SANUWAVE Health, Inc.","BK4082":"医疗保健设备"},"translate_title":"收入指引下调后Sanuwave股价暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNWV":0.9},"content_text":"By Freddy Sebastian \n\n\n  Sanuwave Health said it expects third-quarter revenue of $11.4 million to $11.6 million, below its previous expectations, blaming uncertainty around proposed reimbursement changes for some treatment modalities. \n\n\n  Its stock dropped 20.4% to $32.50 in after-hours trading on Monday. \n\n\n  The company, which develops patented noninvasive, biological response activating devices, previously expected revenue between $12 million and $12.7 million for its three-month period ended Sept. 30. \n\n\n  The uncertainty affected purchase decisions, which were delayed and patient counts were reduced as providers took a wait-and-see approach to potential changes, CEO Morgan Frank said. \"This made for a difficult environment,\" he added. \n\n\n  As a result, Sanuwave said it cut its revenue forecast for fiscal 2025 to between $44 million to $46 million from previous guidance of $48 million to $50 million. \n\n\n  Write to Freddy Sebastian at freddy.sebastian@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 06, 2025 16:52 ET (20:52 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}